Ezatiostat is a tripeptide glutathione analog with isoform‐specific inhibitory action on GSTP1 catalytic activity, and has been used in pre‐clinical models and clinical studies of patients with myelodysplasia to stimulate normal myeloblasts proliferation.[40] Our study showed in organoid‐derived xenografts, ezatiostat alone led to significant tumor reduction at comparable extent and tempo as crizotinib treatment, while co‐treatment resulted in significantly augmented tumor shrinkage. Here, GSTP1 is linked to Myelodysplasia.